HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Lovastatin as treatment for neurocognitive deficits in neurofibromatosis type 1: phase I study.

Abstract
In a neurofibromatosis type 1 murine model, treatment with lovastatin reversed cognitive disabilities. We report on a phase I study examining the safety and tolerability of lovastatin in children with neurofibromatosis type 1. Twenty-four children with neurofibromatosis type 1 underwent a dose-escalation protocol for 3 months to identify the maximum tolerated dose and potential toxicity. Minimal side effects were evident, and no child experienced dose-limiting toxicity. Cognitive evaluations were completed before and after treatment, and the results suggested improvement in areas of verbal and nonverbal memory. Additional analyses, using reliable change indices, indicated improvements exceeding those of test-retest or practice effects in some participants. These observations may be analogous to the improvements observed in a neurofibromatosis type 1 murine model treated with lovastatin, although further study and replication are required. The safety and preliminary cognitive results support the need for a larger phase II trial in this population.
AuthorsMaria T Acosta, Peter G Kardel, Karin S Walsh, Kenneth N Rosenbaum, Gerard A Gioia, Roger J Packer
JournalPediatric neurology (Pediatr Neurol) Vol. 45 Issue 4 Pg. 241-5 (Oct 2011) ISSN: 1873-5150 [Electronic] United States
PMID21907886 (Publication Type: Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2011 Elsevier Inc. All rights reserved.
Chemical References
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Lovastatin
Topics
  • Adolescent
  • Child
  • Cognition Disorders (drug therapy, etiology)
  • Drug Administration Schedule
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors (administration & dosage, therapeutic use)
  • Lovastatin (administration & dosage, therapeutic use)
  • Male
  • Neurofibromatosis 1 (complications, drug therapy)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: